Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Bulevirtide for chronic hepatitis delta virus infection	Bulevirtide (Myrcludex B)	Chronic hepatitis D	Hepatology , Infectious Disease	2020	View \| Download
Budesonide-glycopyrronium-formoterol fumarate for the treatment of severe and inadequately controlled asthma	Budesonide-glycopyrronium-formoterol fumarate	Asthma	Respiratory System	2024	View \| Download
Budesonide suspension for treating eosinophilic oesophagitis in children and adolescents	Budesonide orodispersible (Jorveza)	Eosinophilic oesophagitis	Gastroenterology , Immunology	2023	View \| Download
Budesonide granules for induction of remission in lymphocytic colitis – first line	Budesonide gastro-resistant (Budenofalk)	Lymphocytic colitis	Gastroenterology , Immunology	2020	View \| Download
Budesonide for Ulcerative Proctitis	Budesonide gastro-resistant (Budenofalk)	Ulcerative proctitis	Gastroenterology	2021	View \| Download
Brolucizumab for visual impairment due to diabetic macular oedema	Brolucizumab (RTH258; ESBA1008; Beovu)	Visual impairment	Endocrine Nutritional and Metabolic Disorders , Ophthalmology	2020	View \| Download
Brolucizumab (ESBA1008; RTH258) for neovascular age-related macular degeneration (nAMD)	Brolucizumab (RTH258; ESBA1008; Beovu)	Age-related macular degeneration (AMD)	Ophthalmology	2017	View \| Download
Brigatinib for locally advanced or metastatic, ALK-positive, non-small cell lung cancer – first line	Brigatinib (Alunbrig; AP26113)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Brigatinib for ALK-positive, locally advanced or metastatic, non-small cell lung cancer previously treated with alectinib or ceritinib	Brigatinib (Alunbrig; AP26113)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer	Brigatinib (Alunbrig; AP26113)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download